InsidersTradesSigma
Follow the Delcath Systems, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Delcath Systems, INC. has recorded 36 insider filings. Market capitalisation: €442.2m. The latest transaction was reported on 6 March 2026 (Acquisition). Among the most active insiders: SALAMON STEVEN A J. All data is openly available.
36
Insider Decl.
n/a
Thresholds
€6m
32 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Delcath Systems, INC. Strong Buy (bullish), based on 5 analysts. Average price target: US$21.55.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,742 of 29,062 companies
53.4
score / 100
Value48
Quality59
FCF yld4.0%
Earn yld0.5%
EV/EBITDA·
ROE0.5%
Gross mgn86%
Net mgn3.2%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 March 2026
Declarations36 total
5,533 shares@ US$9.04100.0% of flowCommon StockSEC:0001824817-26-000006:0
Canonical exit: 4 Jun 2026 (T+90)
11,200 shares@ US$8.956220.5% of flowCommon StockSEC:0001235644-26-000007:0
Canonical exit: 31 May 2026 (T+90)
4,386 shares@ US$8.89100.0% of flowCommon StockSEC:0001784561-25-000005:0
Canonical exit: 19 Feb 2026 (T+90)
11,500 shares@ US$8.52625.6% of flowCommon StockSEC:0001235644-25-000004:0
Canonical exit: 9 Feb 2026 (T+90)
42,000 shares@ US$4.78100.0% of flowCommon StockSEC:0001415889-25-017260:0
3,300 shares@ US$4.610.0038% mcap15.6% of flowCommon StockSEC:0000899243-22-018540:0
Canonical exit: 14 Aug 2022 (T+90)
5,000 shares@ US$5.0270.0063% mcap5.8% of flowCommon SharesSEC:0001019056-22-000388:0
Canonical exit: 11 Aug 2022 (T+90)
6,000 shares@ US$4.9040.0074% mcap6.8% of flowCommon SharesSEC:0001019056-22-000384:0
Canonical exit: 10 Aug 2022 (T+90)
1,600 shares@ US$6.250.0024% mcap0.1% of flowCommon SharesSEC:0001019056-22-000358:0
Canonical exit: 18 Jul 2022 (T+90)
1,600 shares@ US$6.250.0024% mcap2.2% of flowCommon SharesSEC:0001019056-22-000356:0
Canonical exit: 18 Jul 2022 (T+90)
2,000 shares@ US$6.34870.0031% mcap0.1% of flowCommon SharesSEC:0001019056-22-000354:0
Canonical exit: 17 Jul 2022 (T+90)
2,000 shares@ US$6.34870.0031% mcap100.0% of flowCommon SharesSEC:0001019056-22-000352:0
Canonical exit: 17 Jul 2022 (T+90)
200 shares@ US$6.340.0003% mcap0.2% of flowCommon StockSEC:0000899243-22-015014:0
Canonical exit: 17 Jul 2022 (T+90)
1,500 shares@ US$6.450.0023% mcap0.1% of flowCommon SharesSEC:0001019056-22-000344:0
Canonical exit: 12 Jul 2022 (T+90)
1,500 shares@ US$6.450.0023% mcap2.1% of flowCommon SharesSEC:0001019056-22-000340:0
Canonical exit: 12 Jul 2022 (T+90)
2,500 shares@ US$6.480.0039% mcap0.1% of flowCommon SharesSEC:0001019056-22-000334:0
Canonical exit: 11 Jul 2022 (T+90)
2,500 shares@ US$6.480.0039% mcap3.6% of flowCommon SharesSEC:0001019056-22-000332:0
Canonical exit: 11 Jul 2022 (T+90)
5,000 shares@ US$6.590.0079% mcap32.5% of flowCommon StockSEC:0000899243-22-014435:0
Canonical exit: 10 Jul 2022 (T+90)
1,000 shares@ US$6.490.0016% mcap0.1% of flowCommon SharesSEC:0001019056-22-000322:0
Canonical exit: 5 Jul 2022 (T+90)
1,000 shares@ US$6.490.0016% mcap1.4% of flowCommon SharesSEC:0001019056-22-000325:0
Canonical exit: 5 Jul 2022 (T+90)
1,000 shares@ US$6.590.0016% mcap1.2% of flowCommon StockSEC:0000899243-22-014377:0
Canonical exit: 7 Jul 2022 (T+90)
1,600 shares@ US$12.680.0045% mcap18.4% of flowCommon StockSEC:0000899243-22-013801:0
Canonical exit: 17 Feb 2021 (T+90)
2,000 shares@ US$7.560.0035% mcap0.1% of flowCommon SharesSEC:0001019056-22-000012:0
Canonical exit: 30 Mar 2022 (T+90)
2,000 shares@ US$7.560.0035% mcap3.2% of flowCommon SharesSEC:0001019056-22-000014:0
Canonical exit: 30 Mar 2022 (T+90)
23,200 shares@ US$8.610.046% mcap36.3% of flowCommon StockSEC:0000899243-21-046986:0
Canonical exit: 2 Mar 2022 (T+90)
25 of 36 declarations
关于 Delcath Systems, INC.
Delcath Systems, Inc. 是一家总部位于美国的肿瘤学医疗公司，在美国纳斯达克资本市场上市，股票代码为DCTH。该公司成立于1988年，其核心使命是开发肝脏靶向药物输送系统，旨在向肝脏输送高剂量化疗药物，同时减少全身暴露。其运营总部位于纽约州昆斯伯里，这使得Delcath具有一家专注于美国医疗保健的小型股公司的形象，并具有强大的临床和监管背景。（[investors.delcath.com](https://investors.delcath.com/ir-resources/faqs?utm_source=openai)） Delcath的业务围绕两个商业平台展开。在美国，其旗舰产品是HEPZATO KIT，这是一种药物/器械组合产品，用于治疗原发性和转移性肝癌，特别是肝脏主导的疾病。在欧洲，该公司销售CHEMOSAT，这是其肝脏输送系统的基于器械的版本，用于专门的医疗中心进行肝癌治疗。这创造了一种结合了专业制药、医疗器械以及临床中心激活和支持的商业模式。（[delcath.com](https://delcath.com/about-us/?utm_source=openai)） 从竞争角度来看，Delcath占据了一个狭窄但差异化的利基市场。它不是一个广泛多元化的制药集团；相反，它是一个专注于介入肿瘤学的参与者，解决特定的临床需求：区域性肝脏化疗输送。这种专注可能是一个优势，因为它创造了清晰的治疗定位和潜在可防御的技术平台，但这也意味着业务高度依赖于医生的采纳、报销、监管执行和中心激活的速度。HEPZATO获得FDA批准以及建立特定产品的报销代码是支持采纳和商业化的重要商业里程碑。（[sec.gov](https://www.sec.gov/Archives/edgar/data/872912/000162828026022951/dcth202510kforproxy.pdf?utm_source=openai)） 最近的发展表明了显著的势头。2025年，Delcath报告了主要由HEPZATO KIT推动的强劲收入增长，以及不断改善的毛利率和不断扩大的治疗中心足迹。该公司还推进了其临床特许经营权：CHOPIN数据于2026年在《柳叶刀肿瘤学》上发表，为该平台的临床原理增加了外部验证。对于投资者而言，Delcath仍然是一家具有高经营杠杆的专业美国纳斯达克医疗保健公司，其关键关注点是报销的持久性、商业采纳、临床扩展以及在美国和欧洲的持续执行。（[investors.delcath.com](https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-fourth-quarter-and-full-year-2025?utm_source=openai)）
